Novel_JJ Recombinant_NP Parapoxvirus_NP Vectors_NP Induce_NP Protective_NP Humoral_NP and_CC Cellular_NP Immunity_NP against_IN Lethal_NP Herpesvirus_NP Challenge_NP Infection_NP in_IN Mice_NP Orf_NP virus_NN (_( ORFV_NP ;_: Parapoxvirus_NP ovis_NP )_) was_VBD used_VBN to_TO develop_VB a_DT novel_JJ vector_NN system_NN for_IN the_DT generation_NN of_IN effective_JJ and_CC safe_JJ live_JJ vaccines_NNS ._SENT Based_VBN on_IN the_DT attenuated_JJ ORFV_NP strain_NN D1701-V_NP ,_, recombinants_NNS were_VBD produced_VBN that_WDT express_VBP the_DT glycoproteins_NNS gC_NN (_( D1701-VrVgC_NP )_) or_CC gD_JJ (_( D1701-VrVgD_NN )_) of_IN the_DT alphaherpesvirus_NN of_IN swine_NN ,_, pseudorabies_NP virus_NN (_( PRV_NP )_) ._SENT Expression_NN of_IN gC_NN and_CC gD_NNS was_VBD also_RB demonstrated_VBN on_IN the_DT surface_NN of_IN recombinant_JJ virus-infected_JJ murine_JJ cells_NNS that_WDT do_VBP not_RB produce_VB infectious_JJ ORFV_NP ._SENT Single_JJ or_CC combined_JJ immunization_NN with_IN the_DT ORFV_NP recombinants_NNS protected_VBD different_JJ mouse_NN strains_NNS of_IN a_DT host_NN species_NNS nonpermissive_JJ for_IN ORFV_NP against_IN a_DT fulminant_JJ ,_, lethal_JJ PRV_NP challenge_NN infection_NN equal_JJ to_TO immunization_NN with_IN PRV_NP live_JJ vaccine_NN ._SENT Most_RBS notably_RB ,_, even_RB a_DT single_JJ immunization_NN with_IN D1701-VrVgC_NP was_VBD protective_JJ ,_, whereas_IN two_CD applications_NNS of_IN D1701-VrVgD_NP were_VBD required_VBN for_IN immune_JJ protection_NN ._SENT The_DT higher_JJR protective_JJ capacity_NN of_IN D1701-VrVgC_NP correlated_VBD with_IN the_DT induction_NN of_IN a_DT strong_JJ specific_JJ humoral_JJ immune_JJ response_NN ._SENT This_DT suggestion_NN was_VBD supported_VBN by_IN transfer_NN experiments_NNS using_VBG sera_NN from_IN recombinant-immunized_JJ mice_NNS ,_, which_WDT resulted_VBD in_IN partial_JJ gC_NN but_CC not_RB gD_JJ antibody-mediated_JJ protection_NN of_IN the_DT naive_JJ recipients_NNS ._SENT Remarkably_RB ,_, immunization_NN of_IN different_JJ immune-deficient_JJ mice_NNS demonstrated_VBD that_IN the_DT application_NN of_IN the_DT PRV_NP gC-expressing_NN recombinant_JJ controlled_VBN the_DT challenge_NN infection_NN in_IN the_DT absence_NN of_IN either_DT CD4+_NP or_CC CD8+_NP T_NN cells_NNS ,_, B_NP cells_NNS ,_, or_CC an_DT intact_JJ perforin_NN pathway_NN ._SENT In_IN contrast_NN ,_, D1701-VrVgD-immunized_JJ mice_NNS lacking_VBG CD4+_NP T_NN cells_NNS exhibited_VBD reduced_VBN protection_NN ,_, whereas_IN animals_NNS lacking_VBG CD8+_NP T_NN cells_NNS ,_, B_NP cells_NNS ,_, or_CC perforin_NP resisted_VBD the_DT challenge_NN infection_NN ._SENT The_DT present_JJ study_NN demonstrates_VBZ the_DT potential_NN of_IN these_DT new_JJ vector_NN vaccines_NNS to_TO efficiently_RB prime_JJ both_CC protective_JJ humoral_JJ and_CC cell-mediated_JJ immune_JJ mechanisms_NNS in_IN a_DT host_NN species_NNS nonpermissive_JJ for_IN the_DT vector_NN virus_NN ._SENT Vaccines_NNS based_VBN on_IN live_JJ virus_NN are_VBP excellent_JJ inducers_NNS of_IN long-term_JJ immunity_NN by_IN eliciting_VBG protective_JJ humoral_JJ and_CC cell-mediated_JJ immune_JJ responses_NNS against_IN the_DT inserted_JJ antigen_NN ._SENT To_TO this_DT end_NN ,_, poxviruses_NNS are_VBP one_CD of_IN the_DT most_RBS versatile_JJ expression_NN systems_NNS for_IN foreign_JJ antigens_NNS and_CC have_VBP been_VBN considered_VBN as_IN vectors_NNS for_IN human_JJ and_CC veterinary_JJ live_JJ vaccines_NNS ._SENT Long-term_JJ immunity_NN induced_VBN by_IN vaccinia_NN virus_NN (_( VACV_NP )_) or_CC other_JJ poxviruses_NNS ,_, however_RB ,_, might_MD result_VB in_IN unsuccessful_JJ revaccination_NN or_CC reduced_VBN protection_NN against_IN VACV-encoded_JJ foreign_JJ antigens_NNS ._SENT For_IN safety_NN reasons_NNS ,_, different_JJ strategies_NNS are_VBP used_VBN to_TO develop_VB attenuated_JJ ,_, host-restricted_JJ ,_, or_CC replication-deficient_JJ poxviruses_NNS ,_, which_WDT retain_VBP their_PP$ ability_NN to_TO activate_VB the_DT host_NN 's_POS immune_JJ response_NN (_( for_IN review_NN ,_, see_VBP references_NNS and_CC )_) ._SENT The_DT host_NN range-restricted_VBD attenuated_JJ VACV_NP strain_NN MVA_NP (_( modified_VBN VACV_NP Ankara_NP )_) was_VBD found_VBN to_TO induce_VB lower_JJR levels_NNS of_IN VACV-neutralizing_VBG antibodies_NNS than_IN wild-type_NP VACV_NP and_CC is_VBZ currently_RB widely_RB used_VBN as_IN a_DT vector_NN vaccine_NN ._SENT It_PP cannot_MD grow_VB in_IN human_JJ cells_NNS and_CC is_VBZ propagated_VBN on_IN primary_JJ chicken_NN embryo_NN fibroblasts_NNS (_( CEFs_NP )_) ._SENT Avipoxvirus_NN vectors_NNS ,_, which_WDT show_VBP an_DT abortive_JJ replication_NN in_IN mammalian_JJ cells_NNS ,_, are_VBP also_RB produced_VBN in_IN CEFs_NP ._SENT However_RB ,_, products_NNS from_IN CEFs_NP do_VBP not_RB represent_VB optimal_JJ safety_NN profiles_NNS due_JJ to_TO different_JJ adventitious_JJ contaminants_NNS ,_, in_IN contrast_NN to_TO production_NN in_IN permanent_JJ cell_NN lines_NNS ._SENT Recently_RB ,_, the_DT genus_NN Parapoxvirus_NP (_( PPV_NP )_) of_IN the_DT family_NN Poxviridae_NNS ,_, and_CC in_IN particular_RB the_DT type_NN species_NN Orf_NP virus_NN (_( ORFV_NP )_) ,_, has_VBZ been_VBN proposed_VBN as_IN candidate_NN for_IN novel_JJ vector_NN vaccines_NNS ._SENT Arguments_NNS in_IN favor_NN of_IN an_DT ORFV_NP vector_NN include_VBP the_DT very_RB restricted_VBN host_NN range_NN (_( sheep_NN and_CC goats_NNS )_) ,_, its_PP$ tropism_NN restricted_VBN to_TO the_DT skin_NN ,_, the_DT lack_NN of_IN systemic_JJ infection_NN ,_, a_DT short-term_JJ vector-specific_JJ protective_JJ immunity_NN ,_, and_CC the_DT exceptionally_RB strong_JJ stimulation_NN of_IN fast_JJ innate_JJ cellular_JJ immune_JJ mechanisms_NNS at_IN the_DT site_NN of_IN infection_NN (_( for_IN review_NN ,_, see_VBP references_NNS and_CC )_) ._SENT In_IN addition_NN to_TO cytokines_NNS ,_, chemokines_NNS ,_, and_CC alpha/beta_NN interferon_NN (_( IFN-alpha/beta_NP )_) as_IN part_NN of_IN the_DT host_NN 's_POS inflammatory_JJ response_NN against_IN the_DT infection_NN ,_, major_JJ histocompatibility_NN complex_JJ class_NN II-positive_JJ dendritic_JJ cells_NNS accumulate_VBP in_IN the_DT infected_JJ skin_NN ,_, which_WDT represent_VBP professional_JJ antigen-presenting_NN cells_NNS for_IN the_DT subsequent_JJ induction_NN of_IN a_DT specific_JJ immune_JJ response_NN ._SENT CD4+_JJ T_NN cells_NNS dominate_VBP the_DT local_JJ accumulation_NN of_IN B_NN and_CC T_NN cells_NNS and_CC were_VBD found_VBN to_TO be_VB of_IN importance_NN for_IN the_DT development_NN of_IN ORFV-specific_JJ antibodies_NNS ._SENT It_PP is_VBZ worthwhile_JJ to_TO stress_VB the_DT short-lived_JJ duration_NN of_IN ORFV-specific_JJ immunity_NN ,_, which_WDT allows_VBZ frequent_JJ reinfections_NNS ._SENT A_DT most_RBS important_JJ feature_NN of_IN ORFV_NP in_IN the_DT context_NN with_IN its_PP$ use_NN as_IN a_DT vaccine_NN is_VBZ the_DT absence_NN of_IN systemic_JJ virus_NN spread_NN ,_, even_RB in_IN immunocompromised_JJ individuals_NNS or_CC after_IN intravenous_JJ injection_NN of_IN high_JJ virus_NN doses_NNS ._SENT Occasional_JJ transmission_NN of_IN wild-type_NP ORFV_NP to_TO humans_NNS often_RB remains_VBZ unrecognized_JJ ._SENT A_DT prime_JJ candidate_NN for_IN use_NN as_IN a_DT recombinant_JJ vector_NN is_VBZ the_DT highly_RB attenuated_JJ ,_, cell_NN culture-adapted_JJ ORFV_NP strain_NN D1701_NP ,_, which_WDT is_VBZ almost_RB apathogenic_JJ in_IN sheep_NN ._SENT This_DT attenuated_JJ virus_NN strain_NN possesses_VBZ various_JJ immunostimulatory_JJ properties_NNS (_( for_IN review_NN ,_, see_VBP reference_NN )_) ._SENT After_IN adaptation_NN of_IN D1701_NP on_IN the_DT nonruminant_JJ Vero_NP cell_NN line_NN ,_, a_DT new_JJ variant_NN (_( D1701-V_NP )_) was_VBD obtained_VBN without_IN altered_JJ immunogenic_JJ properties_NNS and_CC also_RB lacking_VBG pathogenicity_NN ,_, even_RB in_IN immunosuppressed_JJ sheep_NN ._SENT To_TO investigate_VB the_DT immunogenicity_NN of_IN recombinant_JJ ORFV_NP against_IN a_DT clinically_RB relevant_JJ pathogen_NN ,_, the_DT Alphaherpesvirus_NP of_IN swine_NN ,_, Pseudorabies_NNS virus_NN (_( PRV_NP ;_: Herpesvirus_NP suis_NNS type_NN 1_CD )_) was_VBD chosen_VBN ._SENT The_DT neurotropic_JJ PRV_NP has_VBZ a_DT broad_JJ host_NN range_NN with_IN a_DT high_JJ mortality_NN ,_, including_VBG rodents_NNS ,_, which_WDT are_VBP used_VBN as_IN models_NNS to_TO investigate_VB the_DT role_NN of_IN viral_JJ proteins_NNS in_IN neurotropism_NN and_CC neurovirulence_NN of_IN PRV_NP (_( for_IN review_NN ,_, see_VBP reference_NN )_) ._SENT Moreover_RB ,_, mice_NNS are_VBP commonly_RB used_VBN to_TO investigate_VB immunorelevant_JJ virus_NN components_NNS in_IN the_DT PRV-specific_JJ immune_JJ response_NN as_IN well_RB as_RB to_TO evaluate_VB the_DT immunogenicity_NN and_CC protective_JJ capacity_NN of_IN vaccines_NNS against_IN lethal_JJ PRV_NP infection_NN ._SENT Among_IN the_DT 10_CD different_JJ PRV_NP glycoproteins_NNS ,_, particularly_RB the_DT glycoproteins_NNS gB_NN ,_, gC_NN ,_, and_CC gD_NNS are_VBP important_JJ for_IN the_DT antiviral_JJ humoral_JJ and_CC cellular_JJ immune_JJ responses_NNS ._SENT Several_JJ reports_NNS demonstrated_VBD some_DT protective_JJ effect_NN after_IN passive_JJ immunization_NN with_IN anti-gC_NN and_CC anti-gD_NN antibodies_NNS and_CC the_DT immunogenic_JJ relevance_NN of_IN gC_NN and_CC gD_NN by_IN using_VBG recombinant_JJ VACVs_NP or_CC glycoprotein-encoding_NP plasmid_NP DNA_NP for_IN immunization_NN ._SENT The_DT present_JJ study_NN describes_VBZ the_DT generation_NN of_IN ORFV_NP recombinants_NNS expressing_VBG the_DT PRV_NP glycoproteins_NNS gC_NN and_CC gD_NN ,_, which_WDT are_VBP correctly_RB processed_VBN in_IN ORFV_NP permissive_JJ and_CC nonpermissive_JJ cell_NN cultures_NNS ._SENT The_DT attenuated_JJ ORFV_NP strain_NN D1701-VrV_NP was_VBD used_VBN as_IN parental_JJ virus_NN for_IN recombinant_JJ construction_NN ,_, in_IN which_WDT the_DT Escherichia_NP coli_NNS lacZ_NN gene_NN replaces_VBZ the_DT virus-encoded_JJ VEGF-E_NN gene_NN ,_, which_WDT is_VBZ a_DT functional_JJ homologue_NN of_IN the_DT mammalian_JJ vascular_JJ endothelial_JJ growth_NN factor_NN and_CC represents_VBZ an_DT important_JJ virulence_NN factor_NN of_IN ORFV_NP ._SENT The_DT results_NNS presented_VBD demonstrate_VB the_DT powerful_JJ potential_NN of_IN this_DT vector_NN system_NN to_TO protect_VB against_IN a_DT fulminant_JJ ,_, lethal_JJ herpesvirus_NN infection_NN ._SENT Even_RB single_JJ immunization_NN with_IN a_DT mixture_NN of_IN both_DT recombinants_NNS or_CC with_IN the_DT gC-expressing_VBG D1701-VrV_NP recombinant_JJ alone_RB protected_VBN mice_NNS against_IN a_DT lethal_JJ PRV_NP challenge_NN infection_NN ._SENT Experiments_NNS using_VBG different_JJ immune-deficient_JJ mice_NNS revealed_VBD that_IN the_DT induced_VBN PRV_NP glycoprotein_NN gC-specific_JJ humoral_JJ response_NN is_VBZ necessary_JJ ,_, although_IN not_RB sufficient_JJ to_TO control_VB the_DT challenge_NN infection_NN ._SENT Moreover_RB ,_, it_PP was_VBD found_VBN that_IN the_DT ORFV_NP recombinant-induced_JJ immune_JJ mechanisms_NNS are_VBP able_JJ to_TO compensate_VB for_IN the_DT lack_NN of_IN either_DT B_NP cells_NNS ,_, CD4+_NP or_CC CD8+_NP T_NN cells_NNS ,_, or_CC perforin_NN ._SENT Cells_NNS and_CC virus_NN ._SENT |_SYM The_DT attenuated_JJ ORFV_NP strain_NN D1701_NP ,_, originally_RB propagated_VBN in_IN the_DT bovine_JJ kidney_NN cell_NN line_NN BKKL-3A_NP ,_, was_VBD adapted_VBN to_TO the_DT simian_JJ cell_NN line_NN Vero_NP (_( D1701-V_NP )_) and_CC propagated_VBD as_RB described_VBN recently_RB ._SENT After_IN appearance_NN of_IN cytopathogenic_JJ effect_NN (_( CPE_NP )_) ,_, cells_NNS were_VBD harvested_VBN after_IN trypsin_NN treatment_NN (_( 0.125_CD mg/ml_NN ;_: Difco_NP ,_, Augsburg_NP ,_, Germany_NP )_) and_CC centrifuged_VBN at_IN 30,000_CD x_NN g_NN ,_, and_CC the_DT resulting_VBG pellet_NN was_VBD sonified_VBN ._SENT Titration_NN and_CC plaque_NN purification_NN of_IN virus_NN were_VBD performed_VBN with_IN Vero_NP cells_NNS in_IN six-well_NN plates_NNS with_IN 0.9_CD %_NN (_( wt/vol_NN )_) agarose_NN (_( SeaPlaque_NP agarose_NN ;_: BMA_NP ,_, Rockland_NP ,_, Maine_NP )_) in_IN minimal_JJ essential_JJ medium_NN ._SENT The_DT recombinant_JJ ORFV_NP D1701-VrV_NP contains_VBZ the_DT functional_JJ E._NP coli_NNS lacZ_NN gene_NN replacing_VBG the_DT viral_JJ VEGF-E_NN gene_NN ,_, which_WDT is_VBZ present_JJ in_IN two_CD copies_NNS due_JJ to_TO its_PP$ location_NN in_IN the_DT inverted_JJ terminal_NN repeats_NNS of_IN the_DT D1701_NP genome_NN (_( Fig._NN and_CC B_NN )_) After_IN removal_NN of_IN the_DT VEGF-E_JJ gene_NN ,_, a_DT lacZ_NP gene_NN cassette_NN was_VBD inserted_VBN into_IN the_DT EcoRV_NP site_NN of_IN plasmid_NN pdV550_NN ._SENT Construction_NN of_IN recombinant_JJ transfer_NN plasmids_NNS ._SENT |_SYM For_IN insertion_NN into_IN the_DT VEGF-E_JJ gene_NN locus_NN of_IN ORFV_NP D1701-V_NP ,_, the_DT PRV_NP glycoprotein_NN genes_NNS were_VBD cloned_VBN into_IN plasmid_NP pdV-Rec1_NP ,_, which_WDT was_VBD obtained_VBN by_IN linker_NN insertion_NN of_IN a_DT multiple_JJ cloning_VBG site_NN into_IN pdV550_NN ._SENT The_DT complete_JJ coding_VBG sequence_NN of_IN the_DT PRV_NP gC_NN gene_NN was_VBD excised_VBN from_IN plasmid_NP pALM-20_NP (_( generously_RB provided_VBN by_IN L._NP W._NP Enquist_NP ,_, Princeton_NP University_NP ,_, Princeton_NP ,_, N.J._NP )_) as_IN a_DT 1.47-kbp_JJ NcoI-HinfI_NP fragment_NN ._SENT After_IN fill-in_NN reaction_NN with_IN Klenow_NP polymerase_NN ,_, this_DT fragment_NN was_VBD blunt_JJ end_NN ligated_VBN into_IN the_DT single_JJ EcoRV_NP site_NN of_IN pdVRec1_NN ,_, resulting_VBG in_IN plasmid_NN pdVgC_NN ._SENT The_DT complete_JJ PRV_NP gD_NN gene_NN was_VBD obtained_VBN from_IN plasmid_NP pgDBSII_NP (_( kindly_RB provided_VBN by_IN A._NP Jestin_NP ,_, AFSSA_NP ,_, Ploufragan_NP ,_, France_NP )_) by_IN HindIII-BamHI_NP digestion_NN and_CC subsequently_RB ligated_VBN into_IN the_DT HindIII_NP and_CC BamHI_NP sites_NNS of_IN pdVRec1_NN ,_, resulting_VBG in_IN plasmid_NN pdVgD_NNS ._SENT The_DT correct_JJ construction_NN of_IN all_DT plasmids_NNS was_VBD verified_VBN with_IN restriction_NN enzyme_NN digests_NNS and_CC DNA_NP sequencing_NP ._SENT Generation_NN and_CC selection_NN of_IN recombinant_JJ viruses_NNS ._SENT |_SYM For_IN the_DT generation_NN of_IN ORFV_NP recombinants_NNS expressing_VBG PRV_NP gC_NP (_( D1701-VrVgC_NP )_) or_CC gD_JJ (_( D1701-VrVgD_NP )_) ,_, Vero_NP cells_NNS were_VBD infected_VBN with_IN D1701-VrV_NP at_IN a_DT multiplicity_NN of_IN infection_NN (_( MOI_NP )_) of_IN 0.1_CD 50_CD %_NN tissue_NN culture_NN infectious_JJ dose_NN (_( TCID50_NP )_) and_CC were_VBD transfected_VBN 2_CD h_NN later_JJR with_IN 2_CD mug_NN of_IN the_DT recombinant_JJ transfer_NN plasmid_NN (_( pdVgC_NN or_CC pdVgD_NNS )_) and_CC 4_CD mul_NN of_IN SuperFect_NP transfection_NN reagent_NN according_VBG to_TO the_DT recommendations_NNS of_IN the_DT manufacturer_NN (_( Qiagen_NP ,_, Hilden_NP ,_, Germany_NP )_) ._SENT Four_CD days_NNS later_RBR ,_, the_DT cells_NNS were_VBD lysed_VBN by_IN multiple_JJ freeze-thawing_NN cycles_NNS and_CC plaque_NN titrated_VBN on_IN Vero_NP cells_NNS ._SENT Using_VBG a_DT 1_CD %_NN SeaPlaque_NN agarose_NN overlay_VBD containing_VBG 300_CD mug_NN of_IN Bluo-Gal_NP per_IN ml_NP (_( Invitrogen_NP Life_NP Technologies_NPS ,_, Karlsruhe_NP ,_, Germany_NP )_) ,_, white_JJ virus_NN plaques_NNS could_MD be_VB identified_VBN after_IN successful_JJ exchange_NN of_IN the_DT lacZ_NP gene_NN cassette_NN in_IN D1701-VrV_NP ._SENT Immunostaining_VBG of_IN virus_NN plaques_NNS with_IN a_DT polyclonal_JJ goat_NN anti-PRV_NN serum_NN (_( diluted_VBN 1:500_CD )_) ,_, peroxidase-conjugated_JJ antigoat_NN immunoglobulin_NN G_NP (_( IgG_NP )_) antibodies_NNS (_( diluted_VBN 1:500_CD ;_: Dianova_NP ,_, Hamburg_NP ,_, Germany_NP )_) ,_, and_CC the_DT Vector-VIP_NP substrate_NN kit_NN for_IN peroxidase_NN (_( Vector_NP Laboratories_NP ,_, Burlingame_NP ,_, Calif._NP )_) confirmed_VBD expression_NN of_IN the_DT foreign_JJ genes_NNS ._SENT After_IN three_CD to_TO four_CD consecutive_JJ rounds_NNS of_IN plaque_NN purification_NN ,_, virus_NN stocks_NNS were_VBD prepared_VBN in_IN Vero_NP cells_NNS ._SENT For_IN immunization_NN ,_, virus_NN stocks_NNS were_VBD briefly_RB sonicated_VBN ,_, and_CC cell_NN debris_NN was_VBD removed_VBN by_IN centrifugation_NN before_IN virus_NN titration_NN ._SENT DNA_NN analyses_NNS ._SENT |_SYM Viral_NP DNA_NP of_IN the_DT recombinant_JJ viruses_NNS was_VBD prepared_VBN according_VBG to_TO the_DT alkaline_JJ lysis_NN procedure_NN followed_VBN by_IN phenol_NN extraction_NN as_IN described_VBN in_IN reference_NN ._SENT Restriction_NN endonuclease_NN analysis_NN of_IN the_DT purified_VBN viral_JJ DNA_NN and_CC Southern_JJ blot_NN hybridization_NN were_VBD performed_VBN as_IN described_VBN previously_RB with_IN PRV_NP glycoprotein_NN gene-specific_NN or_CC lacZ_NN gene-specific_NN ,_, radioactively_RB labeled_VBN probes_NNS ._SENT RNA_NP isolation_NN and_CC Northern_JJ blot_NN hybridization_NN ._SENT |_SYM For_IN enrichment_NN of_IN viral_JJ early_JJ RNA_NP ,_, cells_NNS were_VBD pretreated_VBN with_IN 100_CD mug_NN of_IN cycloheximide_NN (_( CH_NP )_) per_IN ml_NN for_IN 1_CD h_NN before_IN infection_NN (_( MOI_NP of_IN 10_CD )_) ._SENT After_IN an_DT additional_JJ 8_CD h_NN in_IN the_DT presence_NN of_IN CH_NP ,_, total_JJ cellular_JJ RNA_NP was_VBD prepared_VBN with_IN TriZOL_NP reagent_NN (_( Invitrogen_NP Life_NP Technologies_NPS ,_, Leek_NP ,_, The_DT Netherlands_NPS )_) ._SENT RNA_NP (_( 10_CD mug_NN )_) was_VBD separated_VBN in_IN formaldehyde-containing_VBG agarose_JJ gels_NNS and_CC transferred_VBN onto_IN nylon_NN membranes_NNS (_( Hybond_NP N+_NP ;_: Amersham_NP Biosciences_NP ,_, Freiburg_NP ,_, Germany_NP )_) ._SENT Hybridization_NN using_VBG PRV_NP glycoprotein_NN gene-specific_NP or_CC ORFV_NP ANK3_NP gene-specific_NP probes_NNS was_VBD performed_VBN overnight_RB at_IN 45C_JJ in_IN a_DT mixture_NN containing_VBG 3x_NP SSPE_NP (_( 1x_NP SSPE_NP is_VBZ 0.18_CD M_NP NaCl_NP ,_, 10_CD mM_NP NaH2PO4_NP ,_, and_CC 1_CD mM_NP EDTA_NP [_SYM pH_NN 7.7_CD ]_SYM )_) ,_, 1.0_CD %_NN nonfat_NN dried_VBD milk_NN ,_, 2.0_CD %_NN sodium_NN dodecyl_NN sulfate_NN (_( SDS_NP )_) ,_, 0.5_CD %_NN (_( vol/vol_NN )_) diethyl-pyrocarbonate_NN (_( DEPC_NP ;_: Serva_NP ,_, Heidelberg_NP ,_, Germany_NP )_) ,_, 7.0_CD %_NN (_( wt/vol_NN )_) dextran_NN sulfate_NN ,_, and_CC 60_CD %_NN deionized_JJ formamide_NN (_( Invitrogen_NP Life_NP Technologies_NPS )_) ._SENT Western_JJ blot_NN analysis_NN ._SENT |_SYM Cells_NP infected_VBN at_IN an_DT MOI_NP of_IN 10_CD were_VBD harvested_VBN ,_, collected_VBN by_IN centrifugation_NN ,_, and_CC lysed_VBD in_IN a_DT mixture_NN of_IN 12.5_CD mM_NP Tris-HCl_NP (_( pH_NN 6.8_CD )_) ,_, 2.5_CD %_NN SDS_NP (_( wt/vol_NN )_) ,_, 10_CD %_NN sucrose_NN (_( wt/vol_NN )_) ,_, 0.02_CD %_NN bromphenol_NN blue_NN (_( wt/vol_NN )_) ,_, and_CC 5_CD %_NN 2-mercaptoethanol_NN (_( vol/vol_NN )_) ._SENT Total_JJ cell_NN proteins_NNS were_VBD resolved_VBN by_IN electrophoresis_NN in_IN an_DT SDS-10_NP %_NN ProSieve_NP 50_CD (_( BMA_NP )_) gel_NN and_CC electroblotted_JJ onto_IN a_DT polyvinylidene_NN difluoride_NN Western_JJ blotting_VBG membrane_NN (_( Roche_NP Applied_NP Sciences_NPS ,_, Mannheim_NP ,_, Germany_NP )_) for_IN 30_CD min_NN at_IN 100_CD V_CD in_IN a_DT mixture_NN of_IN 25_CD mM_NP Tris_NP ,_, 192_CD mM_NP glycine_NN ,_, and_CC 20_CD %_NN (_( vol/vol_NN )_) methanol_NN (_( pH_NN 8.6_CD )_) ._SENT The_DT membranes_NNS were_VBD blocked_VBN in_IN TBST_NP buffer_NN (_( 50_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.4_CD ]_SYM ,_, 150_CD mM_NP NaCl_NP ,_, 0.05_CD %_NN Tween_NP 20_CD )_) ,_, containing_VBG 5_CD %_NN nonfat_NN dried_VBD milk_NN for_IN 1_CD h_NN and_CC then_RB incubated_VBN with_IN primary_JJ antibody_NN for_IN 2_CD h_NN at_IN room_NN temperature_NN ._SENT To_TO this_DT end_NN ,_, undiluted_JJ PRV_NP gC-specific_JJ mouse_NN monoclonal_NN hybridoma_NN supernatant_JJ A18b_NP containing_VBG 1_CD %_NN nonfat_NN dried_VBD milk_NN ,_, the_DT polyclonal_JJ PRV_NP gD-specific_JJ rabbit_NN antiserum_NN 016/00_CD (_( diluted_VBN 1:2,500_CD in_IN TBST_NP containing_VBG 1_CD %_NN nonfat_NN dried_VBN milk_NN )_) ,_, or_CC the_DT monoclonal_NN antibody_NN (_( MAb_NP )_) 4D9_JJ (_( diluted_VBN 1:100_LS )_) directed_VBN against_IN the_DT 39K_JJ major_JJ envelope_NN protein_NN of_IN ORFV_NP was_VBD used_VBN ._SENT After_IN being_VBG washed_VBN with_IN TBST_NP ,_, the_DT membranes_NNS were_VBD incubated_VBN for_IN 1_CD h_NN with_IN a_DT 1:100_CD dilution_NN of_IN species-specific_JJ secondary_JJ anti-IgG_NN (_( H+L_NP )_) antibodies_NNS conjugated_VBN to_TO peroxidase_NN (_( Dianova_NP )_) followed_VBD by_IN staining_VBG with_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) containing_VBG 20_CD %_NN methanol_NN ,_, 0.02_CD %_NN diaminobenzidine_NN ,_, 0.06_CD %_NN chloronaphthol_NN ,_, and_CC 0.006_CD %_NN H2O2_NP ._SENT Fluorescent_JJ analysis_NN of_IN protein_NN surface_NN expression_NN ._SENT |_SYM For_IN flow_NN cytometric_JJ analyses_NNS using_VBG the_DT FACSCalibur_NP fluorescence-activated_JJ cell_NN sorter_NN (_( FACS_NP )_) (_( Becton_NP Dickinson_NP ,_, Heidelberg_NP ,_, Germany_NP )_) ,_, cells_NNS were_VBD harvested_VBN 24_CD h_NN after_IN infection_NN (_( MOI_NP of_IN 10_CD )_) and_CC immunostained_VBN with_IN the_DT PRV_NP gC-specific_JJ MAb_NP A18b_NP or_CC with_IN the_DT 1:100-diluted_JJ PRV_NP gD-specific_JJ antiserum_NN 016/00_CD and_CC 1:100-diluted_JJ species-specific_JJ secondary_JJ anti-IgG_NN (_( H+L_NP )_) antibodies_NNS conjugated_VBN to_TO fluorescein_NN isothiocyanate_NN (_( Dianova_NP )_) ._SENT All_DT incubations_NNS and_CC washing_NN steps_NNS were_VBD performed_VBN at_IN 4C_JJ in_IN PBS_NP containing_VBG 3_CD %_NN fetal_JJ bovine_JJ serum_NN ._SENT Mice_NNS ._SENT |_SYM Wild-type_NP BALB/c_NP ,_, C57BL/6_NP ,_, and_CC 129/Sv/Ev_NP mice_NNS and_CC mutant_JJ CD4-/-_NP 129/Sv/Ev_NP ,_, B-cell_NN deficient_JJ C57BL/6_NP (_( muMT_NP )_) ,_, CD8-/-_NP C57BL/6_NP ,_, or_CC perforin-/-_NP C57BL/6_NP (_( PKOB_NP )_) mice_NNS were_VBD used_VBN ._SENT All_DT of_IN these_DT mice_NNS were_VBD kindly_RB provided_VBN by_IN R._NP M._NP Zinkernagel_NP (_( Institute_NP for_IN Experimental_NP Immunology_NP ,_, University_NP of_IN Zurich_NP ,_, Zurich_NP ,_, Switzerland_NP )_) and_CC bred_VBN at_IN the_DT Federal_NP Research_NP Center_NP for_IN Virus_NP Diseases_NPS of_IN Animals_NPS ,_, Tuebingen_NP ,_, Germany_NP ._SENT Mice_NNS of_IN both_DT sexes_NNS were_VBD challenge_NN infected_VBN at_IN 8_CD to_TO 10_CD weeks_NNS of_IN age_NN ._SENT Immunization_NN and_CC challenge_NN infection_NN of_IN mice_NNS ._SENT |_SYM Mice_NN were_VBD injected_VBN intramuscularly_RB (_( i.m._JJ )_) with_IN 107_CD TCID50s_NNS of_IN the_DT ORFV_NP recombinants_NNS expressing_VBG the_DT PRV_NP glycoproteins_NNS in_IN a_DT total_JJ volume_NN of_IN 0.2_CD ml_NN (_( 0.1_CD ml_NN for_IN each_DT hind_JJ leg_NN )_) ._SENT Immunization_NN was_VBD repeated_VBN at_IN 2-week_JJ intervals_NNS ,_, and_CC 2_CD weeks_NNS after_IN the_DT last_JJ immunization_NN ,_, mice_NNS were_VBD bled_VBN from_IN the_DT retroorbital_JJ plexus_NN for_IN serum_NN collection_NN ._SENT Immediately_RB thereafter_RB ,_, the_DT BALB/c_NP mice_NNS were_VBD challenge_NN infected_VBN intraperitoneally_RB (_( i.p._JJ )_) with_IN 102_CD PFU_NN (_( corresponding_JJ to_TO 30_CD 50_CD %_NN lethal_JJ doses_NNS [_SYM LD50s_NP ]_SYM )_) of_IN the_DT highly_RB virulent_JJ PRV_NP strain_NN NIA-3_NP ,_, and_CC the_DT C57BL/6_NP and_CC 129/Sv/Ev_NP mice_NNS were_VBD infected_VBN with_IN 103_CD PFU_NN (_( corresponding_JJ to_TO 25_CD LD50s_NN )_) ._SENT The_DT LD50_NP was_VBD determined_VBN for_IN each_DT wild-type_NN mouse_NN strain_NN (_( four_CD animals_NNS per_IN group_NN )_) by_IN i.p._JJ infection_NN using_VBG serial_JJ dilutions_NNS of_IN PRV_NP NIA-3_NP ranging_VBG from_IN 105_CD to_TO 3.3_CD PFU_NN ,_, and_CC was_VBD calculated_VBN as_IN described_VBN previously_RB ._SENT As_IN negative_JJ controls_NNS ,_, mice_NNS were_VBD immunized_VBN with_IN 107_CD TCID50s_NNS of_IN the_DT parental_JJ ORFV_NP D1701-VrV_NP ,_, and_CC as_IN positive_JJ controls_NNS ,_, mice_NNS were_VBD immunized_VBN with_IN 107_CD PFU_NN of_IN the_DT PRV_NP live_JJ vaccine_NN Begonia_NP (_( Intervet_NP International_NP BV_NP ,_, Boxmeer_NP ,_, The_DT Netherlands_NPS )_) ._SENT Antibody_NN analyses_NNS ._SENT |_SYM Sera_NP from_IN immunized_VBN and_CC control_NN mice_NNS were_VBD analyzed_VBN for_IN PRV-specific_NP IgG1_NP and_CC IgG2a_NP antibodies_NNS by_IN enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) using_VBG PRV-coated_JJ microtiter_NN plates_NNS and_CC substrate_NN of_IN the_DT commercially_RB available_JJ Checkit_NP Aujeszkytest_NP II_NP (_( Intervet_NP ,_, Unterschleissheim_NP ,_, Germany_NP )_) ._SENT The_DT plates_NNS were_VBD incubated_VBN with_IN serial_JJ twofold_JJ dilutions_NNS (_( starting_VBG with_IN a_DT 1:80_CD dilution_NN )_) of_IN each_DT serum_NN for_IN 90_CD min_NN at_IN 37C_JJ ,_, washed_VBN as_IN recommended_VBN ,_, and_CC incubated_VBN with_IN 1:5,000-diluted_JJ biotinylated_JJ goat_NN anti-mouse_NN IgG1_NP or_CC biotinylated_JJ goat_NN anti-mouse_NN IgG2a_NP antibody_NN (_( Southern_NP Biotechnology_NP ,_, Birmingham_NP ,_, Ala._NP )_) for_IN 90_CD min_NN at_IN 37C_JJ ._SENT The_DT plates_NNS were_VBD washed_VBN and_CC incubated_VBN with_IN a_DT 1:2,000_CD dilution_NN of_IN peroxidase-conjugated_JJ avidin_NN (_( BD_NP PharMingen_NP )_) for_IN 1_CD h_NN at_IN 37C_JJ ._SENT Antibody_NN titers_NNS were_VBD expressed_VBN as_IN the_DT reciprocal_NN of_IN a_DT serum_NN dilution_NN exhibiting_VBG an_DT at_IN least_JJS twofold_JJ increase_NN in_IN optical_JJ density_NN over_IN that_DT of_IN the_DT negative_JJ control_NN serum_NN that_WDT was_VBD obtained_VBN from_IN D1701-VrV-immunized_JJ mice_NNS ._SENT The_DT standard_JJ deviation_NN was_VBD calculated_VBN from_IN the_DT mean_JJ titer_NN of_IN sera_NN obtained_VBN from_IN the_DT individual_JJ mice_NNS (_( eight_CD animals_NNS per_IN group_NN immunized_VBN separately_RB with_IN the_DT individual_JJ ORFV_NP recombinants_NNS and_CC five_CD animals_NNS per_IN group_NN vaccinated_VBN with_IN PRV_NP live_JJ vaccine_NN or_CC with_IN a_DT combination_NN of_IN both_DT recombinants_NNS )_) ._SENT Serum_NN neutralizing_VBG antibodies_NNS directed_VBN against_IN PRV_NP were_VBD determined_VBN by_IN a_DT complement-independent_JJ neutralization_NN assay_NN ._SENT Sera_NP were_VBD inactivated_VBN at_IN 56C_NN for_IN 30_CD min_NN ,_, and_CC twofold_JJ dilutions_NNS of_IN the_DT sera_NN (_( starting_VBG with_IN a_DT dilution_NN of_IN 1:20_CD )_) were_VBD incubated_VBN in_IN triplicates_NNS together_RB with_IN 50_CD PFU_NP of_IN PRV_NP strain_NN NIA-3_NP for_IN 90_CD min_NN at_IN 37C_JJ in_IN flat-bottom_NN 96-well_NN plates_NNS ._SENT Thereafter_RB ,_, Vero_NP cells_NNS were_VBD added_VBN ,_, and_CC 3_CD days_NNS later_RBR ,_, the_DT serum_NN neutralizing_VBG antibody_NN titer_NN was_VBD determined_VBN as_IN the_DT highest_JJS serum_NN dilution_NN resulting_VBG in_IN 100_CD %_NN reduction_NN of_IN CPE_NP ._SENT In_IN vitro_NN characterization_NN of_IN D1701_JJ recombinants_NNS in_IN ORFV_NP permissive_JJ cells_NNS ._SENT |_SYM Virus_NP recombinants_NNS were_VBD selected_VBN and_CC plaque_NN purified_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT The_DT correct_JJ substitution_NN of_IN both_DT copies_NNS of_IN lacZ_NN by_IN the_DT PRV_NP gC_NN and_CC gD_NN genes_NNS ,_, respectively_RB ,_, was_VBD verified_VBN by_IN Southern_NP blot_NN hybridization_NN with_IN probes_NNS specific_JJ for_IN lacZ_NP ,_, gC_NN ,_, or_CC gD_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT Specific_JJ transcription_NN of_IN the_DT PRV_NP glycoprotein_NN genes_NNS ,_, which_WDT are_VBP controlled_VBN by_IN the_DT strong_JJ early_JJ VEGF-E_NN promoter_NN ,_, was_VBD examined_VBN by_IN Northern_JJ blot_NN analysis_NN of_IN total_JJ RNA_NP isolated_VBD 8_CD h_NN postinfection_NN (_( p.i._JJ )_) from_IN CH-treated_JJ cells_NNS ._SENT The_DT results_NNS demonstrated_VBD specific_JJ transcription_NN of_IN early_JJ mRNA_NN of_IN the_DT expected_VBN size_NN for_IN gC_NN (_( Fig._NN lane_NN 1_CD )_) as_IN well_RB as_RB for_IN gD_NN (_( Fig._NN ,_, lane_NN 2_CD )_) ._SENT To_TO control_VB for_IN comparable_JJ levels_NNS of_IN viral_JJ gene_NN expression_NN in_IN the_DT cells_NNS infected_VBN with_IN the_DT individual_JJ recombinants_NNS ,_, the_DT transcription_NN rate_NN of_IN the_DT early_JJ ORFV_NP gene_NN ANK-3_NP was_VBD tested_VBN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, cells_NNS infected_VBN with_IN D1701-VrVgC_NP (_( lane_NN 1_CD )_) ,_, D1701-VrVgD_NP (_( lane_NN 2_CD )_) ,_, or_CC the_DT parental_JJ virus_NN ,_, D1701-VrV_NP (_( lane_NN 3_CD )_) ,_, synthesized_VBD comparable_JJ amounts_NNS of_IN viral_JJ mRNA_NN ._SENT In_IN addition_NN ,_, each_DT PRV_NP glycoprotein_NN gene-specific_NN probe_NN detected_VBD a_DT transcript_NN approximately_RB 3.8_CD kb_NN in_IN size_NN ,_, which_WDT was_VBD not_RB found_VBN in_IN uninfected_JJ cells_NNS (_( lane_NN 4_CD )_) ._SENT This_DT can_MD be_VB explained_VBN by_IN partial_JJ read-through_NN of_IN the_DT early_JJ transcription_NN stop_NN motif_NN (_( T5NT_NP )_) of_IN the_DT original_JJ VEGF-E_NN by_IN using_VBG another_DT stop_NN motif_NN 1.65_CD kb_NN downstream_JJ ,_, as_RB also_RB found_VBN for_IN the_DT ANK-3_NP gene_NN ._SENT In_IN addition_NN ,_, Northern_JJ blot_NN analysis_NN also_RB demonstrated_VBD substantial_JJ foreign_JJ gene_NN expression_NN at_IN later_JJR times_NNS p.i._JJ in_IN the_DT absence_NN of_IN CH_NP (_( data_NN not_RB shown_VBN )_) ,_, which_WDT is_VBZ also_RB found_VBN for_IN the_DT VEGF-E_JJ gene_NN of_IN D1701-V_NP (_( M._NP Henkel_NP and_CC H.-J_NP ._SENT Rziha_NP ,_, unpublished_JJ data_NNS )_) ._SENT Translation_NN of_IN the_DT PRV_NP glycoproteins_NNS was_VBD tested_VBN in_IN cells_NNS infected_VBN with_IN each_DT D1701-VrV_NP recombinant_JJ by_IN Western_JJ blot_NN analysis_NN ._SENT Using_VBG the_DT gC-specific_JJ MAb_NP A18b_NP ,_, all_DT known_VBN processing_NN products_NNS of_IN gC_NN ,_, the_DT 58-kDa_NP precursor_NN ,_, the_DT 74-kDa_NP pre-Golgi_NN form_NN ,_, and_CC the_DT 92-kDa_NNS mature_VBP form_NN could_MD be_VB demonstrated_VBN in_IN D1701-VrVgC-infected_JJ cells_NNS (_( Fig._NN ,_, lane_NN 1_CD )_) as_IN in_IN PRV-infected_JJ cells_NNS (_( Fig._NN ,_, lane_NN 5_CD )_) ._SENT Similarly_RB ,_, cells_NNS infected_VBN with_IN D1701-VrVgD_NP exhibited_VBD authentic_JJ expression_NN of_IN gD_NNS compared_VBN to_TO PRV-infected_JJ cells_NNS ._SENT The_DT gD-specific_JJ polyclonal_JJ antiserum_NN detected_VBD the_DT precursor_NN (_( 45_CD kDa_NNS )_) and_CC the_DT mature_JJ glycosylated_JJ form_NN (_( 60_CD kDa_NNS )_) of_IN gD_NN ._SENT Comparable_JJ synthesis_NN of_IN both_DT forms_NNS of_IN the_DT ORFV_NP major_JJ envelope_NN protein_NN (_( 39_CD and_CC 31_CD kDa_NNS )_) was_VBD found_VBN in_IN Vero_NP cells_NNS infected_VBN with_IN the_DT recombinant_JJ viruses_NNS and_CC the_DT parental_JJ D1701-VrV_NP ,_, which_WDT indicated_VBD similar_JJ viral_JJ protein_NN synthesis_NN ._SENT Finally_RB ,_, flow_NN cytometry_NN demonstrated_VBD surface_NN expression_NN of_IN gC_NN or_CC gD_NN on_IN Vero_NP cells_NNS infected_VBN with_IN the_DT individual_JJ D1701-VrV_NP recombinants_NNS ,_, but_CC an_DT approximately_RB 10-fold-higher_JJ synthesis_NN of_IN gC_NN than_IN of_IN gD_NN (_( Fig._NN and_CC D_NN )_) ._SENT This_DT is_VBZ in_IN agreement_NN with_IN the_DT Western_JJ blot_NN results_NNS ,_, although_IN a_DT comparable_JJ amount_NN of_IN the_DT specific_JJ transcripts_NNS seemed_VBD to_TO be_VB synthesized_VBN in_IN the_DT productively_RB infected_JJ Vero_NP cells_NNS ,_, and_CC both_DT recombinants_NNS grew_VBD to_TO equal_VB virus_NN titers_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT From_IN the_DT experiments_NNS done_VBN ,_, the_DT reasons_NNS for_IN a_DT lower_JJR level_NN of_IN gD_JJ synthesis_NN in_IN permissive_JJ Vero_NP cells_NNS compared_VBN to_TO the_DT level_NN of_IN gC_NN synthesis_NN remain_VBP obscure_JJ and_CC need_VBP further_JJR investigation_NN ._SENT Expression_NN of_IN gC_NN and_CC gD_NN in_IN D1701-VrV_NP recombinant-infected_JJ cells_NNS nonpermissive_JJ for_IN ORFV_NP ._SENT |_SYM Since_IN one_CD objective_NN of_IN this_DT study_NN was_VBD to_TO evaluate_VB the_DT efficiency_NN of_IN the_DT D1701-VrV_NP recombinants_NNS in_IN mice_NNS ,_, a_DT nonpermissive_JJ host_NN for_IN ORFV_NP ,_, the_DT foreign_JJ gene_NN expression_NN and_CC production_NN of_IN infectious_JJ progeny_NN were_VBD tested_VBN in_IN mouse_NN cell_NN lines_NNS ._SENT Northern_JJ and_CC Western_JJ blot_NN analyses_NNS of_IN 3T3_JJ and_CC L929_JJ cells_NNS infected_VBN with_IN D1701-VrVgC3_NP or_CC D1701-VrVgD_NP showed_VBD the_DT correct_JJ expression_NN of_IN both_DT PRV_NP glycoproteins_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT In_IN contrast_NN to_TO the_DT permissive_JJ Vero_NP cells_NNS ,_, surface_NN expression_NN of_IN comparable_JJ amounts_NNS of_IN gC_NN and_CC gD_NNS was_VBD found_VBN by_IN flow_NN cytometry_NN in_IN both_DT mouse_NN cell_NN lines_NNS infected_VBN with_IN the_DT individual_JJ recombinant_JJ virus_NN (_( Fig._NN ,_, C_NP ,_, E_NP ,_, and_CC F_NN )_) ._SENT ORFV_NP production_NN was_VBD tested_VBN by_IN titration_NN experiments_NNS (_( single-step_VB virus_NN growth_NN curve_NN )_) in_IN 3T3_JJ and_CC L929_JJ cells_NNS infected_VBN with_IN a_DT D1701-VrVgC3_NP MOI_NP of_IN 1.0_CD or_CC 10.0_CD ._SENT Production_NN of_IN infectious_JJ progeny_NN was_VBD detectable_JJ in_IN neither_DT cell_NN lysates_VBZ (_( Fig._NN and_CC C_NP )_) nor_CC supernatants_NNS of_IN both_DT infected_JJ mouse_NN cell_NN lines_NNS (_( Fig._NN and_CC D_NP )_) ,_, whereas_IN high_JJ titers_NNS of_IN the_DT recombinant_JJ viruses_NNS were_VBD produced_VBN in_IN Vero_NP cells_NNS (_( Fig._NN ,_, solid_JJ triangles_NNS )_) indistinguishable_JJ from_IN those_DT with_IN the_DT parental_JJ D1701-VrV_NP (_( data_NN not_RB shown_VBN )_) ._SENT Collectively_RB ,_, the_DT results_NNS demonstrate_VBP the_DT in_IN vitro_NN expression_NN of_IN the_DT inserted_JJ PRV_NP glycoproteins_NNS also_RB on_IN the_DT surface_NN of_IN infected_JJ cells_NNS nonpermissive_JJ for_IN ORFV_NP ._SENT PRV-specific_JJ serum_NN antibody_NN response_NN in_IN immunized_VBN mice_NNS ._SENT |_SYM To_TO evaluate_VB the_DT immunogenicity_NN of_IN the_DT PRV_NP gC-_NN and_CC gD-expressing_VBG ORFV_NP recombinants_NNS ,_, three_CD different_JJ mouse_NN strains_NNS ,_, BALB/c_NP ,_, 129/Sv/Ev_NP ,_, and_CC C57BL/6_NP ,_, were_VBD immunized_VBN i.m._JJ up_RB to_TO three_CD times_NNS at_IN 2-week_JJ intervals_NNS ._SENT Groups_NNS of_IN animals_NNS were_VBD vaccinated_VBN with_IN D1701-VrVgC_NP and_CC D1701-VrVgD_NP alone_RB or_CC in_IN combination_NN at_IN 107_CD TCID50s_NNS per_IN dose_NN ._SENT As_IN controls_NNS ,_, animals_NNS were_VBD immunized_VBN with_IN the_DT same_JJ dose_NN of_IN a_DT PRV_NP live_JJ vaccine_NN (_( Begonia_NP )_) ,_, with_IN the_DT parental_JJ D1701-VrV_NP ,_, or_CC with_IN PBS_NP ._SENT PRV-specific_JJ serum_NN antibodies_NNS of_IN IgG1_NP and_CC IgG2a_NP subclasses_NNS were_VBD determined_VBN by_IN ELISA_NP ._SENT As_IN shown_VBN in_IN Fig._NN immunization_NN of_IN BALB/c_NP mice_NNS with_IN the_DT PRV_NP live_JJ vaccine_NN induced_VBD higher_JJR specific_JJ IgG2a_NP than_IN IgG1_NP serum_NN antibody_NN titers_NNS ,_, very_RB similar_JJ to_TO the_DT results_NNS found_VBN after_IN a_DT single_JJ combined_JJ immunization_NN with_IN D1701-VrVgC_NP plus_CC D1701-VrVgD_NP ._SENT A_DT second_JJ combined_JJ immunization_NN increased_VBD the_DT specific_JJ IgG1_NP and_CC IgG2a_NP antibody_NN titers_NNS 16-fold_NN and_CC 4-fold_NN ,_, respectively_RB ,_, whereas_IN a_DT third_JJ immunization_NN did_VBD not_RB change_VB that_DT picture_NN ._SENT Essentially_RB the_DT same_JJ results_NNS were_VBD found_VBN in_IN the_DT various_JJ immunization_NN regimens_NNS in_IN 129/Sv/Ev_NP mice_NNS ._SENT In_IN contrast_NN ,_, significantly_RB lower_JJR titers_NNS of_IN IgG2a_NP serum_NN antibodies_NNS to_TO PRV_NP were_VBD found_VBN after_IN all_DT immunizations_NNS of_IN C57BL/6_NP mice_NNS ,_, resulting_VBG in_IN a_DT slight_JJ prevalence_NN of_IN the_DT specific_JJ IgG1_NP subclass_NN ._SENT Individual_JJ immunizations_NNS with_IN both_DT D1701-VrV_NP recombinants_NNS were_VBD performed_VBN to_TO determine_VB their_PP$ contribution_NN to_TO the_DT antigen-specific_JJ immune_JJ response_NN ._SENT The_DT ELISA_NP results_NNS demonstrated_VBD that_IN the_DT specific_JJ IgG1_NP and_CC IgG2a_NP serum_NN antibody_NN titers_NNS induced_VBN by_IN D1701-VrVgC_NP in_IN the_DT different_JJ mouse_NN strains_NNS were_VBD nearly_RB identical_JJ to_TO those_DT found_VBN after_IN the_DT first_JJ and_CC second_JJ immunizations_NNS with_IN the_DT combination_NN of_IN both_DT recombinants_NNS ._SENT In_IN contrast_NN ,_, no_DT specific_JJ serum_NN antibodies_NNS were_VBD detectable_JJ after_IN a_DT single_JJ application_NN of_IN D1701-VrVgD_NN ,_, and_CC after_IN the_DT second_JJ immunization_NN ,_, approximately_RB 30-_CD to_TO 85-fold-lower_JJ titers_NNS of_IN PRV-specific_NP IgG1_NP and_CC IgG2a_NP antibodies_NNS were_VBD induced_VBN in_IN all_DT mouse_NN strains_NNS (_( Fig._NN to_TO C_NP )_) ._SENT Due_JJ to_TO the_DT generally_RB low_JJ induction_NN of_IN specific_JJ antibodies_NNS by_IN D1701-VrVgD_NP ,_, no_DT antigen-specific_JJ IgG2a_NP serum_NN antibodies_NNS were_VBD detectable_JJ after_IN the_DT second_JJ immunization_NN of_IN C57BL/6_NP mice_NNS ._SENT These_DT results_NNS suggest_VBP a_DT prevalence_NN of_IN a_DT PRV_NP gC-specific_JJ antibody_NN response_NN after_IN simultaneous_JJ immunization_NN with_IN D1701-VrVgC_NP and_CC D1701-VrVgD_NP ._SENT Finally_RB ,_, sera_NN were_VBD tested_VBN for_IN the_DT presence_NN of_IN complement-independent_JJ PRV-neutralizing_JJ antibodies_NNS ._SENT All_DT sera_NN obtained_VBN after_IN the_DT first_JJ immunization_NN with_IN either_CC the_DT PRV_NP live_JJ vaccine_NN or_CC with_IN each_DT D1701-VrV_NP recombinant_JJ alone_RB or_CC in_IN combination_NN did_VBD not_RB contain_VB PRV-neutralizing_JJ activity_NN (_( cutoff_NN ,_, dilution_NN of_IN 1:20_CD )_) ._SENT After_IN booster_NN immunization_NN ,_, the_DT sera_NN of_IN all_DT three_CD mouse_NN strains_NNS exhibited_VBD low_JJ titers_NNS of_IN PRV-neutralizing_JJ antibodies_NNS ._SENT A_DT third_JJ combined_JJ immunization_NN with_IN both_DT recombinants_NNS slightly_RB increased_VBD the_DT titers_NNS of_IN PRV-neutralizing_JJ serum_NN antibodies_NNS ._SENT In_IN conclusion_NN ,_, these_DT results_NNS indicate_VBP that_IN D1701-VrVgC_NP and_CC D1701-VrVgD_NP were_VBD both_DT able_JJ to_TO induce_VB comparable_JJ amounts_NNS of_IN antigen-specific_JJ neutralizing_VBG antibodies_NNS in_IN serum_NN despite_IN their_PP$ clearly_RB different_JJ capabilities_NNS of_IN inducing_VBG antigen-specific_JJ IgG_NP antibodies_NNS ._SENT Protective_JJ capacity_NN of_IN D1701-VrVgC3_NP and_CC D1701-VrVgD_NP ._SENT |_SYM The_DT protection_NN experiments_NNS were_VBD performed_VBN with_IN a_DT 25-_CD to_TO 30-fold_JJ LD50_NP of_IN PRV_NP for_IN challenge_NN infection_NN of_IN the_DT different_JJ mouse_NN strains_NNS (_( eight_CD animals_NNS per_IN group_NN )_) and_CC are_VBP summarized_VBN in_IN Table_NP ._SENT All_DT nonimmunized_JJ (_( PBS_NP )_) or_CC D1701-VrV-immunized_JJ animals_NNS succumbed_VBN to_TO challenge_VB infection_NN within_IN 72_CD to_TO 96_CD h_NN ,_, whereas_IN a_DT single_JJ application_NN of_IN the_DT PRV_NP live_JJ vaccine_NN (_( Begonia_NP )_) protected_VBD all_DT wild-type_NN mouse_NN strains_NNS ._SENT Even_RB a_DT single_JJ i.m._JJ application_NN of_IN the_DT combination_NN of_IN D1701-VrVgC_NP and_CC D1701-VrVgD_NP mediated_VBD 100_CD %_NN protection_NN to_TO C57BL/6_NP or_CC 129/Sv/Ev_NP mice_NNS ,_, and_CC seven_CD of_IN eight_CD BALB/c_NP mice_NNS were_VBD protected_VBN ._SENT The_DT same_JJ protection_NN rates_NNS were_VBD found_VBN after_IN a_DT single_JJ immunization_NN with_IN D1701-VrVgC_NP alone_RB ._SENT Using_VBG D1701-VrVgD_NN ,_, seven_CD of_IN eight_CD C57BL/6_NP or_CC 129/Sv/Ev_NP mice_NNS ,_, but_CC only_RB one_CD of_IN eight_CD immunized_VBD BALB/c_NP mice_NNS ,_, survived_VBD the_DT challenge_NN infection_NN ._SENT Thus_RB ,_, priming_VBG of_IN BALB/c_NP mice_NNS with_IN D1701-VrVgD_NP was_VBD much_RB less_RBR protective_JJ than_IN with_IN D1701-VrVgC_NP ._SENT Two_CD separate_JJ immunizations_NNS with_IN each_DT recombinant_JJ protected_VBN all_DT animals_NNS of_IN each_DT wild-type_NN mouse_NN strain_NN ,_, except_IN for_IN one_CD BALB/c_NP mouse_NN immunized_VBN with_IN D1701-VrVgD_NP ._SENT All_DT protected_JJ animals_NNS were_VBD observed_VBN over_IN a_DT period_NN of_IN up_IN to_TO 9_CD weeks_NNS and_CC did_VBD not_RB show_VB clinical_JJ symptoms_NNS at_IN any_DT time_NN after_IN challenge_NN infection_NN ._SENT Interestingly_RB ,_, BALB/c_NP mice_NNS were_VBD also_RB completely_RB protected_VBN against_IN a_DT 10-fold-higher_JJ dose_NN of_IN challenge_NN virus_NN after_IN two_CD immunizations_NNS with_IN D1701-VrVgC_NP alone_RB or_CC with_IN a_DT combination_NN of_IN both_DT recombinants_NNS ,_, but_CC only_RB 50_CD %_NN of_IN BALB/c_NP mice_NNS immunized_VBD twice_RB with_IN D1701-VrVgD_NP survived_VBD this_DT higher_JJR infectious_JJ dose_NN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT data_NNS show_VBP that_IN already_RB a_DT single_JJ application_NN of_IN the_DT new_JJ ORFV_NP recombinants_NNS could_MD mediate_VB protection_NN of_IN the_DT different_JJ mouse_NN strains_NNS against_IN a_DT lethal_JJ PRV_NP infection_NN ,_, whereby_WRB the_DT recombinant_JJ D1701-VrVgC_NP appeared_VBD to_TO have_VB a_DT higher_JJR protective_JJ capacity_NN ._SENT Serum_NP transfer_NN experiments_NNS ._SENT |_SYM Since_IN a_DT strong_JJ antibody_NN response_NN was_VBD induced_VBN by_IN the_DT gC_NN recombinant_JJ ,_, the_DT role_NN of_IN antigen-specific_JJ serum_NN antibodies_NNS in_IN protection_NN against_IN lethal_JJ challenge_NN infection_NN was_VBD further_RBR scrutinized_VBN ._SENT Therefore_RB ,_, sera_NN from_IN BALB/c_NP mice_NNS immunized_VBD twice_RB with_IN either_DT D1701-VrVgC_NP or_CC D1701-VrVgD_NP were_VBD used_VBN for_IN passive_JJ immunization_NN of_IN naive_JJ recipients_NNS ._SENT Twenty-four_NP hours_NNS after_IN intravenous_JJ transfer_NN of_IN 0.1_CD ,_, 0.3_CD ,_, or_CC 0.5_CD ml_NN of_IN serum_NN ,_, the_DT antigen-specific_JJ antibody_NN titers_NNS of_IN the_DT recipients_NNS were_VBD determined_VBN immediately_RB before_IN challenge_NN infection_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Control_NN animals_NNS received_VBD 0.5_CD ml_NN of_IN serum_NN from_IN mice_NNS immunized_VBN twice_RB with_IN D1701-VrV_NP ,_, and_CC all_RB died_VBD between_IN 72_CD and_CC 96_CD h_NN after_IN challenge_NN infection_NN ._SENT Transfer_NN of_IN 0.1_CD ml_NN of_IN serum_NN from_IN D1701-VrVgC-immunized_JJ mice_NNS (_( DgC_NP serum_NN )_) did_VBD not_RB protect_VB against_IN challenge_NN infection_NN ,_, although_IN the_DT specific_JJ serum_NN antibody_NN titers_NNS (_( 1:530_CD titer_NN of_IN IgG1_NP ,_, 1:1,200_CD titer_NN of_IN IgG2a_NP )_) were_VBD comparable_JJ to_TO those_DT of_IN BALB/c_NP mice_NNS after_IN one_CD active_JJ immunization_NN with_IN D1701-VrVgC_NP mediating_VBG protection_NN (_( Fig._NN and_CC )_) ._SENT However_RB ,_, two_CD BALB/c_NP mice_NNS died_VBD 30_CD to_TO 50_CD h_NN later_JJR compared_VBN to_TO the_DT controls_NNS (_( Fig._NN ,_, squares_NNS )_) ._SENT After_IN passive_JJ immunization_NN with_IN 0.3_CD ml_NN of_IN DgC_NP serum_NN ,_, the_DT recipients_NNS exhibited_VBD higher_JJR serum_NN antibody_NN titers_NNS (_( 1:1,920_CD titer_NN of_IN IgG1_NP ,_, 1:2,970_CD titer_NN of_IN IgG2a_NP )_) than_IN mice_NNS after_IN a_DT single_JJ immunization_NN with_IN live_JJ D1701-VrVgC_NP ;_: nevertheless_RB ,_, only_RB one_CD of_IN six_CD animals_NNS was_VBD protected_VBN ._SENT However_RB ,_, again_RB two_CD animals_NNS survived_VBD 30_CD to_TO 50_CD h_NN longer_JJR than_IN the_DT controls_NNS (_( Fig._NN ,_, circles_NNS )_) ._SENT Finally_RB ,_, compared_VBN to_TO actively_RB single-immunized_JJ BALB/c_NP mice_NNS ,_, approximately_RB threefold-higher_NN antigen-specific_JJ antibody_NN titers_NNS were_VBD found_VBN in_IN the_DT sera_NN of_IN animals_NNS passively_RB immunized_VBN with_IN 0.5_CD ml_NN of_IN DgC_NP serum_NN ,_, but_CC again_RB only_RB a_DT low_JJ level_NN of_IN protection_NN against_IN the_DT PRV_NP challenge_NN infection_NN (_( two_CD of_IN six_CD mice_NNS )_) was_VBD obtained_VBN ._SENT Notably_RB ,_, the_DT death_NN of_IN four_CD mice_NNS of_IN this_DT group_NN was_VBD significantly_RB delayed_JJ (_( Fig._NN ,_, triangles_NNS )_) ._SENT These_DT results_NNS indicate_VBP that_IN PRV_NP gC-specific_JJ serum_NN antibodies_NNS alone_RB are_VBP not_RB sufficient_JJ for_IN protection_NN ._SENT Passive_JJ immunization_NN with_IN sera_NN from_IN D1701-VrVgD-immunized_JJ mice_NNS did_VBD not_RB result_VB in_IN detectable_JJ antibody_NN titers_NNS :_: none_NN of_IN the_DT animals_NNS was_VBD protected_VBN against_IN challenge_NN infection_NN ,_, and_CC the_DT time_NN to_TO death_NN of_IN only_RB two_CD animals_NNS ,_, each_DT receiving_VBG 0.3_CD or_CC 0.5_CD ml_NN of_IN serum_NN ,_, was_VBD prolonged_JJ by_IN 50_CD h_NN ._SENT Immunization_NN of_IN immune-deficient_JJ mice_NNS ._SENT |_SYM To_TO further_RBR elucidate_VB the_DT role_NN of_IN the_DT humoral_JJ response_NN in_IN controlling_VBG the_DT challenge_NN virus_NN ,_, experiments_NNS with_IN B-cell-deficient_JJ muMT_NN mice_NNS were_VBD performed_VBN ._SENT Due_JJ to_TO the_DT finding_NN that_IN the_DT protection_NN rate_NN after_IN combined_JJ immunizations_NNS equaled_VBD that_IN after_IN immunization_NN with_IN D1701-VrVgC_NP alone_RB ,_, in_IN the_DT following_VBG experiments_NNS ,_, mice_NNS were_VBD only_RB immunized_VBN with_IN the_DT individual_JJ recombinants_NNS ._SENT Protection_NN of_IN five_CD of_IN eight_CD muMT_NN mice_NNS was_VBD found_VBN after_IN single_JJ administration_NN of_IN D1701-VrVgC_NP or_CC D1701-VrVgD_NP ,_, respectively_RB (_( data_NNS not_RB shown_VBN )_) ,_, whereas_IN after_IN two_CD immunizations_NNS with_IN each_DT recombinant_JJ alone_RB ,_, seven_CD of_IN eight_CD mice_NNS were_VBD protected_VBN ._SENT With_IN the_DT PRV_NP live_JJ vaccine_NN ,_, four_CD of_IN five_CD muMT_NN mice_NNS were_VBD protected_VBN ._SENT These_DT results_NNS demonstrate_VBP that_IN the_DT Ig-deficient_NP mice_NNS are_VBP still_RB capable_JJ of_IN controlling_VBG challenge_NN infection_NN after_IN the_DT different_JJ immunizations_NNS ._SENT It_PP has_VBZ been_VBN reported_VBN that_IN successful_JJ protection_NN of_IN mice_NNS against_IN lethal_JJ PRV_NP infection_NN might_MD depend_VB on_IN IFN-gamma-producing_NP CD4+_NP T_NN cells_NNS ._SENT To_TO investigate_VB whether_IN similar_JJ immune_JJ effector_NN mechanisms_NNS might_MD be_VB responsible_JJ for_IN the_DT protective_JJ effect_NN of_IN the_DT new_JJ PRV_NP glycoprotein-expressing_NP ORFV_NP recombinants_NNS ,_, 129/Sv/Ev_NP CD4-/-_NP knockout_NN mice_NNS were_VBD investigated_VBN ._SENT The_DT specific_JJ antibody_NN response_NN was_VBD generally_RB lower_JJR in_IN CD4-/-_NP mice_NNS after_IN immunization_NN with_IN the_DT ORFV_NP recombinants_NNS than_IN in_IN wild-type_JJ 129/Sv/Ev_NP mice_NNS ._SENT Single_JJ immunization_NN with_IN D1701-VrVgC_NP induced_VBD two-_NN to_TO threefold-lower_NN PRV-specific_NP IgG1_NP and_CC IgG2a_NP serum_NN antibody_NN levels_NNS than_IN in_IN wild-type_NN mice_NNS ,_, and_CC antigen-specific_JJ serum_NN antibodies_NNS were_VBD not_RB detectable_JJ even_RB after_IN two_CD immunizations_NNS with_IN D1701-VrVgD_NP ._SENT PRV_NP live_JJ vaccination_NN (_( Begonia_NP )_) of_IN the_DT CD4-/-_NP mice_NNS induced_VBD no_DT detectable_JJ IgG1_NP and_CC 16-fold-lower_JJ titers_NNS of_IN specific_JJ IgG2a_NP serum_NN antibodies_NNS compared_VBN to_TO those_DT in_IN wild-type_NN mice_NNS ._SENT Furthermore_RB ,_, none_NN of_IN the_DT sera_NN obtained_VBN from_IN the_DT different_JJ immunizations_NNS exhibited_VBD PRV-neutralizing_JJ activity_NN (_( data_NNS not_RB shown_VBN )_) ._SENT After_IN different_JJ single_JJ immunizations_NNS ,_, CD4-/-_NP mice_NNS were_VBD clearly_RB less_RBR protected_VBN against_IN challenge_NN infection_NN than_IN were_VBD the_DT congenic_JJ 129/Sv/Ev_NP mice_NNS ._SENT Single_JJ administration_NN of_IN D1701-VrVgC_NP protected_VBD 62.5_CD %_NN of_IN the_DT CD4-deficient_JJ animals_NNS ,_, but_CC single_JJ administration_NN of_IN D1701-VrVgD_NP protected_VBD only_RB 25_CD %_NN (_( data_NNS not_RB shown_VBN )_) ,_, and_CC only_RB two_CD of_IN four_CD PRV_NP live-vaccinated_JJ mice_NNS survived_VBD the_DT challenge_NN infection_NN ._SENT However_RB ,_, a_DT booster_NN immunization_NN with_IN D1701-VrVgC_NP protected_VBD all_DT CD4-/-_NP mice_NNS against_IN challenge_NN infection_NN ,_, but_CC only_RB 50_CD %_NN of_IN mice_NNS survived_VBD the_DT challenge_NN infection_NN after_IN two_CD administrations_NNS of_IN the_DT D1701-VrVgD_NN recombinant_JJ ._SENT Altogether_RB ,_, protection_NN of_IN CD4-/-_NP mice_NNS by_IN a_DT single_JJ application_NN of_IN D1701-VrVgC_NP was_VBD reduced_VBN ,_, which_WDT appeared_VBD to_TO correlate_VB with_IN the_DT reduced_VBN induction_NN of_IN specific_JJ antibodies_NNS in_IN serum_NN ,_, but_CC could_MD be_VB compensated_VBN for_IN by_IN a_DT second_JJ immunization_NN ._SENT This_DT was_VBD not_RB the_DT case_NN with_IN D1701-VrVgD_NP ,_, although_IN partial_JJ protection_NN of_IN the_DT CD4-/-_NP mice_NNS could_MD be_VB achieved_VBN ._SENT The_DT reduced_VBN protection_NN of_IN CD4-deficient_JJ mice_NNS mediated_VBN by_IN the_DT ORFV_NP recombinants_NNS might_MD be_VB a_DT consequence_NN of_IN a_DT reduced_VBN capacity_NN of_IN cytolytic_JJ T-cell_NN effector_NN mechanisms_NNS in_IN those_DT animals_NNS ._SENT Therefore_RB ,_, challenge_NN experiments_NNS with_IN perforin_NN knockout_NN (_( PKOB_NP )_) and_CC CD8-deficient_JJ mice_NNS (_( which_WDT had_VBD been_VBN immunized_VBN twice_RB with_IN each_DT recombinant_JJ alone_RB )_) were_VBD performed_VBN ._SENT The_DT results_NNS ,_, however_RB ,_, demonstrated_VBD 100_CD %_NN protection_NN of_IN PKOB_NP or_CC CD8-/-_NP mice_NNS after_IN administration_NN of_IN D1701-VrVgC_NP or_CC D1701-VrVgD_NP ,_, as_RB well_RB as_IN of_IN the_DT PRV_NP live_JJ vaccine_NN ._SENT Therefore_RB ,_, these_DT results_NNS indicate_VBP that_IN after_IN immunization_NN with_IN the_DT new_JJ ORFV_NP recombinants_NNS ,_, the_DT control_NN of_IN the_DT PRV_NP challenge_NN infection_NN can_MD be_VB maintained_VBN in_IN the_DT absence_NN of_IN CD4+_NP or_CC CD8+_NP T_NN cells_NNS ,_, and_CC the_DT perforin_NN pathway_NN seems_VBZ to_TO be_VB not_RB required_VBN for_IN immune_JJ protection_NN ._SENT Like_IN other_JJ poxviruses_NNS ,_, ORFV_NP possesses_VBZ properties_NNS su_NN 